To top it off ZACKS ON THE 11TH PUT A DOWNGRADE --UNDERPERFORM --{what B.S} The gurus at Zacks have no clue--its a technical underperform by ZACKS because of the short sellers they see and knowing more expenses then usual by the next Quarter will be seen because of Nuedexta launch---SO WHAT is ZACKS saying pps hits 10 bucks instead of 15 --15 instead of 20, ZACKS HAD NO EFFECT ON PPS and will eventually change back to neutral or out perform when they see pps climbing with the potential sales of the "ONLY " PBA drug approved out there by the FDA---launch news and BTW ZACKS GAVE NO REASON --LOL
well after what happened right before the approval I am inclined to think that shorters believe they can just run this thing down real quick and cover if they need to. As long as the PPS stays below that critical $5 range that is what shorters will try and do, at least that is what I believe.